^
Association details:
| Biomarker: | TP53 overexpression |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
062 | SAKK 36/13 - IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK
Published date:
06/09/2021
Excerpt:
Since August 2015, 58 pts. received IBR+BOR…In these, IBR+BOR was also effective (ORR 79% (90% CI 62, 90%), n = 28) for Ki-67 >30%, ORR 73% (90% CI 44, 92), n = 11) for p53 overexpression by immunohistochemistry…
Secondary therapy:
bortezomib
DOI:
https://doi.org/10.1002/hon.2879
Trial ID:
